Phase I results of vinorelbine with concurrent radiotherapy in elderly patients with unresectable, locally advanced non-small-cell lung cancer: West Japan Thoracic Oncology Group (WJTOG3005-DI)

International Journal of Radiation Oncology Biology Physics

Volumn 82, Issue 5, 2012, Pages 1777-1782

  Harada, Hideyuki ^a   Seto, Takashi ^b   Igawa, Satoshi ^a,c   Tsuya, Asuka ^a   Wada, Mayuko ^c   Kaira, Kyoichi ^a   Naito, Tateaki ^a   Hayakawa, Kazushige ^c   Nishimura, Tetsuo ^a   Masuda, Noriyuki ^c   Yamamoto, Nobuyuki ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

^c KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemo radiation; Elderly; NSCLC; Phase I; Pneumonitis

Indexed keywords

CHEMO-RADIATION; ELDERLY; NSCLC; PHASE I; PNEUMONITIS;

TOXICITY;

RADIOTHERAPY;

NAVELBINE;

ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; DERMATITIS; DIARRHEA; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPONATREMIA; INCIDENCE; INFECTION; JAPAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PNEUMOTHORAX; PRIORITY JOURNAL; RADIATION DOSE; SENSORY NEUROPATHY; STOMATITIS; THERAPY EFFECT; THROMBOCYTOPENIA;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; DRUG ADMINISTRATION SCHEDULE; ESOPHAGITIS; FEMALE; FEVER; HUMANS; INFECTION; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; NEUTROPENIA; RADIATION PNEUMONITIS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE; VINBLASTINE;

EID: 84858701945     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.03.037     Document Type: Article

References (24)

1. Kaneko S, Ishikawa KB, Yoshimi I, et al. Projection of lung cancer mortality in Japan. Cancer Sci 2003;94:919-923. (Pubitemid 37406976)
2. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer; a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995;311:899-909.
3. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17: 2692-2699. (Pubitemid 29415225)
4. Hanna N, Neubauer M, Yiannoutsos C, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: The Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008;26:5755-5760.
5. Movsas B, Scott C, Sause W, et al. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): A quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies. Int J Radiat Oncol Biol Phys 1999;45:1143-1149.
6. Gridelli C. The ELVIS trial: A phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small-cell lung cancer. Oncologist 2001;6:4-7. (Pubitemid 32155180)
7. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003;95:362-372. (Pubitemid 36395256)
8. Fukuoka K, Arioka H, Iwamoto Y, et al. Mechanism of radiosensitization induced by vinorelbine in human non-small-cell lung cancer cells. Lung Cancer 2001;34:451-460. (Pubitemid 33041481)
9. Gridelli C, Guida C, Barletta E, et al. Thoracic radiotherapy and daily vinorelbine as radiosensitizer in locally advanced non small cell lung cancer:Aphase I study. LungCancer 2000;29:131-137. (Pubitemid 30645822)
10. Sekine I, Noda K, Oshita F, et al. Phase I study of cisplatin, vinorelbine, and concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer. Cancer Sci 2004;95: 691-695. (Pubitemid 39255819)
11. Kobayashi M, Matsui K, Hirashima T, et al. Phase I study of weekly cisplatin, vinorelbine, and concurrent thoracic radiation therapy in patients with locally advanced non-small-cell lung cancer. Int J Clin Oncol 2006;11:314-319. (Pubitemid 44306216)
12. Vokes EE, Haraf DJ, Masters GA, et al. Vinorelbine (navelbine), cisplatin, and concomitant radiation therapy for advanced malignancies of the chest: A phase I study. Semin Oncol 1996; 23(Suppl):48-52. (Pubitemid 26130115)
13. Vokes EE, Herndon JE II, Crawford J, et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and Leukemia Group B study 9431. J Clin Oncol 2002;20:4191-4198. (Pubitemid 35191021)
14. Japan Clinical Oncology Group, Japan Society of Clinical Oncology. Japanese translation of Common Terminology Criteria for Adverse Events (CTCAE), and instructions and guidelines. Int J Clin Oncol 2004;9(Suppl 3):1-82.
15. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
16. Kudoh S, Takeda K, Nakagawa K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: Results of theWest Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 2006;24:3657-3663. (Pubitemid 46630541)
17. Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for nonsmall cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999;45:323-329. (Pubitemid 29408545)
18. Barriger RB, Fakiris AJ, Hanna N, et al. Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel. Int J Radiat Oncol Biol Phys 2010;78:1381-1386.
19. World Health Organization. WHO expert consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363: 157-163.
20. Socinski MA, Zhang C, Herndon JE II, et al. Combined modality trials of the cancer and leukemia group B in stage III nonsmall- cell lung cancer: Analysis of factors influencing survival and toxicity. Ann Oncol 2004;15:1033-1041. (Pubitemid 39089779)
21. Langer C, Scott C, Byhardt R, et al. Effect of advanced age on outcome in radiation therapy oncology group studies of locally advanced NSCLC (LA-NSCLC). Lung Cancer 2000;29:104 [abstract].
22. Movsas B, Scott C, SauseW, et al. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): A quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies. Int J Radiat Oncol Biol Phys 1999;45:1143-1149.
23. Ohe Y, Yamamoto S, Suzuki K, et al. Risk factors of treatmentrelated death in chemotherapy and thoracic radiotherapy for lung cancer. Eur J Cancer 2001;37:54-63. (Pubitemid 32119360)
24. Atagi S, Kawahara M, Tamura T, et al. Standard thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer: A phase III trial of the Japan Clinical Oncology Group (JCOG9812). Jpn J Clin Oncol 2005;35: 195-201. (Pubitemid 40796853)